Polycythemia natural history, complications and prognosis
Polycythemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Polycythemia natural history, complications and prognosis |
FDA on Polycythemia natural history, complications and prognosis |
CDC on Polycythemia natural history, complications and prognosis |
Polycythemia natural history, complications and prognosis in the news |
Blogs on Polycythemia natural history, complications and prognosis |
Risk calculators and risk factors for Polycythemia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]; Zaida Obeidat, M.D.
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of polycythemia vera include:[1]
- Post-PV myelofibrosis (PPMF) in 10% of PV patients
- Leukemic transformation, the most serious complication, can develop in chronic phase, but more frequently during PPMF, spontaneously or associated with chemotherapy or irradiation, particularly in patients age ≥60 years
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Spivak JL (2019). "How I treat polycythemia vera". Blood. 134 (4): 341–352. doi:10.1182/blood.2018834044. PMID 31151982.